Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

ABSTRACT:

Background

The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.

Methods

We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks.

Results

A total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of

SUBMITTER: Hamid O 

PROVIDER: S-EPMC4126516 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature